Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Yesterday, March 18, 2014, 135 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $235.22 to $501,676,000.00. Highlighted Stocks Traded by Insiders: Pfizer (PFE) - FREE Research Report Young John D who is Group President at Pfizer sold 9,000 shares at $31.38 on March 18, 2014. Following this transaction, the Group President owned 99,647 shares meaning that the stake was reduced by 8.28% with the 9,000-share transaction. The shares most recently traded at $31.96, up $0.58, or 1.81% since the insider transaction. Historical insider transactions for Pfizer go as follows:
4-Week # shares sold: 130,817
12-Week # shares sold: 290,817
24-Week # shares sold: 300,817
The average volume for Pfizer has been 25.4 million shares per day over the past 30 days. Pfizer has a market cap of $200.9 billion and is part of the health care sector and drugs industry. Shares are up 4.24% year-to-date as of the close of trading on Tuesday. Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products. The stock currently has a dividend yield of 3.31%. The company has a P/E ratio of 19.0. Currently there are 8 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 2 rate it a hold. Exclusive Offer: Get the latest Stock Analysis on PFE - FREETheStreet Quant Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report from TheStreet Quant Ratings now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.